Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKORN INCAKRX · Entity 146919 | Director | May 09, 2019 | May 13, 2019 |
| HARROW, INC.HROW · Entity 4740 | Director | June 18, 2026 | June 22, 2026 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director | June 10, 2026 | June 12, 2026 |
| Opus Genetics, Inc.IRD · Entity 5892 | Director | April 20, 2026 | April 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKORN INC
Report date May 09, 2019 · Filed May 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,698 |
Reported balance
After 2019-05-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-09 · Grant · Acquired 30,760 · Balance 77,698 F1: The securities acquired are Restricted Stock Units (RSUs) scheduled to vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022 and May 9, 2023. F2: Following the reported transaction, the amount of shares beneficially owned includes 46,610 unvested RSUs and 31,088 shares owned outright. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2029-05-09 | Direct | 58,775 |
Reported balance
After 2019-05-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-09 · Grant · Acquired 58,775 · Balance 58,775 F3: The Stock Options vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022, and May 9, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities acquired are Restricted Stock Units (RSUs) scheduled to vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022 and May 9, 2023.
F2: Following the reported transaction, the amount of shares beneficially owned includes 46,610 unvested RSUs and 31,088 shares owned outright.
F3: The Stock Options vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022, and May 9, 2023.
HARROW, INC.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,248 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 5,248 · Balance 5,248 F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered.
F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service.
OCULAR THERAPEUTIX, INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,000 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,000 · Balance 64,000 F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.74 · Expires 2036-06-09 | Direct | 44,000 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 44,000 · Balance 44,000 F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Opus Genetics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,514 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 24,367 · Balance 127,514 F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 22,088 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-12-11 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 32,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2029-05-14 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2030-06-08 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-05-18 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 15,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.94 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 23,186 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 23:50 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 5,248 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029657 · ownership.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,248 Underlying: Common Stock · 5,248 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:22 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001104659-26-073587 · tm2617745-6_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2036-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:22 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073587 · tm2617745-6_4seq1.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 F1 · shares: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 18, 2026 Filed May 19, 2026 11:00 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock | 1,000 | $31.07 | $31,070.00 |
DisclosureSEC source: 0001493152-26-024342 · ownership.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:31 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 24,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001786 · form4.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,514 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:22 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 23,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000031 · form4.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,147 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2026. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock the day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $1.99 per share, the average of the high and low price of the common stock, the day prior to the grant date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:51 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 7,339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-016322 · ownership.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,339 Underlying: Common Stock · 7,339 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:21 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001104659-25-059379 · tm2517945-1_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:21 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059379 · tm2517945-1_4seq1.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: On June 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:06 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 79,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001428 · form4.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592 Underlying: Common Stock · 79,592 shares Expires 2035-04-29 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:06 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 79,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001428 · form4.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,504 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 21:59 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (right to buy) · Derivative | 172,874 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0000905148-24-002828 · form4.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,874 Underlying: Common Stock · 172,874 shares Expires 2034-10-21 F1 · derivative.exercise_date: The option will vest in a series of three equal annual installments over the three-year period measured from the grant date of October 22, 2024, subject to the Reporting Person's continuing service. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 22:38 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0001104659-24-083096 · tm2420266-1_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-07-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 22:38 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-083096 · tm2420266-1_4seq1.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:00 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 8,347 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-024193 · ownership.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,347 Underlying: Common Stock · 8,347 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:10 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 3,119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004313 · ownership.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,119 Underlying: Common Stock · 3,119 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,186 | Not disclosed Strike: $9.94 | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 7 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,186 shares Expires 2032-05-11 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,500 | Not disclosed Strike: $6.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 6 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2031-05-18 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 5 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2030-06-08 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 4 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2029-05-14 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,000 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 3 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2028-12-11 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerRestricted Stock Units · Derivative | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 14:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerCommon Stock | 22,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080688 · tm2321002-9_4seq1.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 21:18 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001104659-23-080407 · tm2321019-3_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2033-07-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 21:18 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-080407 · tm2321019-3_4seq1.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · shares: On July 10, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant. Read SEC document |
| May 17, 2023 Filed May 19, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000091 · wk-form4_1684533440.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc. F2 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 14,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000074 · wk-form4_1684183672.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date. F2 · derivative.expiration_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 14,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001410939-23-000074 · wk-form4_1684183672.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| May 12, 2022 Filed May 13, 2022 18:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (right to buy) · Derivative | 23,186 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001410939-22-000071 · wf-form4_165247964037531.xml · derivative · entry 4 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,186 Underlying: Common Stock · 23,186 shares Expires 2032-05-11 F4 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted a stock option to purchase 23,186 shares of the Registrant's common stock. Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 12, 2022 Filed May 13, 2022 18:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 14,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000071 · wf-form4_165247964037531.xml · derivative · entry 3 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,588 Underlying: Common Stock · 14,588 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). F3 · derivative.expiration_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 11, 2022 Filed May 13, 2022 18:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000071 · wf-form4_165247964037531.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. F2 · derivative.expiration_date: On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 18:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001410939-22-000071 · wf-form4_165247964037531.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| May 19, 2021 Filed May 20, 2021 19:52 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-070098 · tm2117174-2_4seq1.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F3 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). F3 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 19, 2021 Filed May 20, 2021 19:52 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001104659-21-070098 · tm2117174-2_4seq1.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-05-18 F1 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 14:01 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001104659-20-072340 · a4.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F1 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders. F1 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders. Read SEC document |
| May 15, 2019 Filed May 16, 2019 17:12 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-19-030030 · a4.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Issuer's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:27 UTC | AKORN INC AKRX · Entity 146919 | GrantStock Options (Right to Buy) · Derivative | 58,775 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001144204-19-025734 · tv521508_4.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,775 Underlying: Common Stock · 58,775 shares Expires 2029-05-09 F3 · derivative.exercise_date: The Stock Options vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022, and May 9, 2023. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:27 UTC | AKORN INC AKRX · Entity 146919 | GrantCommon Stock | 30,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-025734 · tv521508_4.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,698 F1 · security: The securities acquired are Restricted Stock Units (RSUs) scheduled to vest in four equal installments on May 9, 2020, May 9, 2021, May 9, 2022 and May 9, 2023. F2 · balance_after: Following the reported transaction, the amount of shares beneficially owned includes 46,610 unvested RSUs and 31,088 shares owned outright. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:11 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001104659-18-073128 · a4.xml · derivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-12-11 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is December 12, 2018. The option vests with respect to one-thirty sixth (1/36th) of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 19, 2018 Filed Apr 23, 2018 19:07 UTC | AKORN INC AKRX · Entity 146919 | GrantCommon Stock | 14,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-002959 · formfour.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,938 F1 · shares: The securities acquired are Restricted Stock Units (RSUs) scheduled to vest in four equal installments on April 19, 2019, April 19, 2020, April 19, 2021 and April 19, 2022. F2 · balance_after: Following the reported transaction, the amount of shares beneficially owned includes 24,607 unvested RSUs and 22,331 shares owned outright. Read SEC document |
| May 04, 2017 Filed May 5, 2017 17:00 UTC | AKORN INC AKRX · Entity 146919 | GrantCommon Stock | 8,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-002736 · f4_050417graves.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 F1 · shares: The securities acquired are Restricted Stock Units (RSUs) scheduled to vest in four equal installments on May 4, 2018, May 4, 2019, May 4, 2020 and May 4, 2021. F2 · balance_after: Following the reported transaction, the amount of shares beneficially owned includes 11,583 unvested RSUs and 21,166 shares owned outright. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:30 UTC | AKORN INC AKRX · Entity 146919 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.87 | $0.00 |
DisclosureSEC source: 0001171843-17-000815 · f4_graves020917.xml · derivative · entry 2 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:30 UTC | AKORN INC AKRX · Entity 146919 | Exercise / conversionCommon Stock | 20,000 | $12.87 | $257,400.00 |
DisclosureSEC source: 0001171843-17-000815 · f4_graves020917.xml · nonDerivative · entry 1 Graves Adrienne L · CIK 0001326192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Following the reported transaction, the amount of shares beneficially owned includes 3,495 unvested shares subject to restricted stock awards and 21,166 shares owned outright. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.